Zealand Pharma sends blood sugar drug to US market

The hypoglycemia treatment Zegalogue is now available on the US market, Zealand Pharma reported on Thursday. Three months ago, the US FDA approved the drug for treating very low blood sugar in patients with diabetes.

Photo: Zealand Pharma / PR

Three months after the US Food and Drug Administration authorized Zealand Pharma's drug for severe hypoglycemia, the Danish biotech firm is sending this treatment to the US market.

A Thursday press release states that the drug will be available as both an auto-injector and a prefilled syringe. Zegalogue is meant to be a rescue therapy for diabetes patients experiencing severe episodes of very low blood sugar.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs